Patents by Inventor David M. Frucht

David M. Frucht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of lymphocytes to measure anthrax lethal toxin activity
    Patent number: 8383359
    Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: February 26, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: David M. Frucht, Hui Fang
  • USE OF LYMPHOCYTES TO MEASURE ANTHRAX LETHAL TOXIN ACTIVITY
    Publication number: 20120122116
    Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.
    Type: Application
    Filed: September 24, 2010
    Publication date: May 17, 2012
    Inventors: David M. Frucht, Hui Fang
  • Anthrax bioassays and methods of treating and diagnosing anthrax infection
    Patent number: 7871790
    Abstract: Based on the observation that exposure of cells or animals to anthrax lethal toxin results in activation of the intracellular enzyme caspase-1/IL-1 converting enzyme (ICE), which, in turn, leads to production and extracellular release of the cytokine substrates of ICE: interleukin 1 beta (IL-1?) and interleukin 18 (IL-18), disclosed herein are bioassays that can be used to determine the efficacy of a potential anthrax therapeutic agent and for screening test agents to identify anthrax therapeutic agents. Also disclosed herein are methods of diagnosing and treating anthrax infection.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: January 18, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David M. Frucht, Ruth Cordoba-Rodriguez
  • Use of lymphocytes to measure anthrax lethal toxin activity
    Patent number: 7803565
    Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.
    Type: Grant
    Filed: April 5, 2006
    Date of Patent: September 28, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David M. Frucht, Hui Fang
  • USE OF LYMPHOCYTES TO MEASURE ANTHRAX LETHAL TOXIN ACTIVITY
    Publication number: 20100227349
    Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.
    Type: Application
    Filed: April 5, 2006
    Publication date: September 9, 2010
    Inventors: David M. Frucht, Hui Fang